Pacira (PCRX) BioSciences reported it has received a Paragraph IV Certification Notice Letter from Qilu Pharmaceutical, a private Chinese company. Qilu has filed an Abbreviated New Drug Application, or ANDA, with the FDA for a product claiming to be a generic equivalent of EXPAREL.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX: